000150543 001__ 150543
000150543 005__ 20250210102457.0
000150543 0247_ $$2doi$$a10.1093/ecco-jcc/jjae178
000150543 0248_ $$2sideral$$a142601
000150543 037__ $$aART-2024-142601
000150543 041__ $$aeng
000150543 100__ $$0(orcid)0000-0002-2945-7368$$aLópez De-La-Cruz, Julia
000150543 245__ $$aImpact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease
000150543 260__ $$c2024
000150543 5203_ $$aBackground: HLADQA1*05 is recently associated with heightened immunogenicity to anti-tumor necrosis factor (TNFα). We aimed to determine whether HLADQ1*05 is a risk factor for primary non-response, loss of response (LOR), or adverse events (AE) to first-line anti-TNFα in patients with inflammatory bowel disease.
Methods: We performed a retrospective observational study enrolling biologic naïve patients with Crohn’s disease and ulcerative colitis who initiated adalimumab or infliximab from 2000 to 2021. HLA-DQA1 genotype was determined in all patients and immunogenicity in 98 patients.
Results: We enrolled 408 patients who started first-line infliximab (n = 211) and adalimumab (n = 197), with a mean follow-up of 7.6 years. Primary response at Week 24 occurred in 347 (85.0%), LOR in 133 (38.3%), and AE in 93 (22.8%). The HLADQA1*05 was identified in 185 (43.3%) patients. In multivariate analyses, no risk factors were identified for primary response. HLADQA1*05 was an independent risk factor for LOR (adjusted hazard ratio [aHR] = 1.80, 95% CI = 1.21-2.67) and immunogenicity (aOR = 3.44, 95% CI = 1.12-11.92). HLADQA1*03 was a protective factor against LOR (aHR = 0.42, 95% CI = 0.20-0.88). Stratified analysis by anti-TNF type showed that HLADQA1*05 increased the risk of LOR to infliximab but not to adalimumab and HLADQA1*03 decreased the risk of LOR to adalimumab but not to infliximab. Female sex, infliximab, and the co-presentation of at least one allele of the HLADQA1*03 and HLADQA1*05 were risk factors for AE.
Conclusions: HLADQA1*05 is associated with a higher risk of LOR and immunogenicity, particularly to infliximab. HLADQA1*03 seems to play a protective role against LOR, particularly adalimumab. Female sex and infliximab are risk factors for AE.
000150543 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000150543 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000150543 700__ $$0(orcid)0000-0003-0076-3529$$aGomollón, Fernando$$uUniversidad de Zaragoza
000150543 700__ $$aLouro, Javier
000150543 700__ $$aLópez Pérez, Juan
000150543 700__ $$aNocito Colon, María Mercedes
000150543 700__ $$aGallego Llera, Beatriz
000150543 700__ $$aGarcía-Mateo, Sandra$$uUniversidad de Zaragoza
000150543 700__ $$aMartínez-Domínguez, Samuel J$$uUniversidad de Zaragoza
000150543 700__ $$0(orcid)0000-0002-9962-6147$$aAso Gonzalvo, María Concepción
000150543 700__ $$0(orcid)0000-0002-3545-2707$$aGargallo-Puyuelo, Carla J$$uUniversidad de Zaragoza
000150543 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000150543 773__ $$g20 (2024), 1-10$$pJ. Crohns Colitis$$tJournal of Crohn's & colitis$$x1873-9946
000150543 8564_ $$s733876$$uhttps://zaguan.unizar.es/record/150543/files/texto_completo.pdf$$yVersión publicada$$zinfo:eu-repo/date/embargoEnd/2025-11-21
000150543 8564_ $$s2064902$$uhttps://zaguan.unizar.es/record/150543/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada$$zinfo:eu-repo/date/embargoEnd/2025-11-21
000150543 909CO $$ooai:zaguan.unizar.es:150543$$particulos$$pdriver
000150543 951__ $$a2025-02-10-08:27:58
000150543 980__ $$aARTICLE